69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7
Titel:
69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7
Auteur:
O'Byrne, K.J. Park, K. Tan, E. Zhang, L. Hirsh, V. Boyer, M. Yang, J.C. Mok, T. Kim, M. Massey, D. Zazulina, V. Paz-Ares, L.